Weiss Ratings Reaffirms Hold (C-) Rating for Regeneron Pharmaceuticals (NASDAQ:REGN)

Key Points

• Weiss Ratings has reaffirmed a "Hold (C-)" rating for Regeneron Pharmaceuticals (NASDAQ: REGN) in a recent research report.
• Regeneron's stock has a consensus rating of "Moderate Buy" with a target price of $817.67, according to analysts.
• The company reported strong quarterly earnings, with an EPS of $12.89, exceeding the consensus estimate by $4.46 and showing a year-over-year revenue increase of 3.6%.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report)'s stock had its "hold (c-)" rating reissued by equities researchers at Weiss Ratings in a research report issued on Wednesday,Weiss Ratings reports.

REGN has been the subject of several other research reports. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a research report on Friday, August 1st. Argus lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. Rothschild & Co Redburn assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price objective for the company. Citigroup reissued a "buy" rating and issued a $650.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Finally, Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 14th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $563.86 on Wednesday. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $1,024.36. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The company has a 50 day moving average price of $573.34 and a 200 day moving average price of $566.14. The firm has a market capitalization of $59.76 billion, a price-to-earnings ratio of 14.21, a price-to-earnings-growth ratio of 1.86 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter in the prior year, the business posted $11.56 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Marietta Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals by 30.2% during the 1st quarter. Marietta Wealth Management LLC now owns 10,778 shares of the biopharmaceutical company's stock valued at $6,836,000 after acquiring an additional 2,501 shares during the last quarter. Sepio Capital LP boosted its stake in Regeneron Pharmaceuticals by 33.1% during the 1st quarter. Sepio Capital LP now owns 3,389 shares of the biopharmaceutical company's stock valued at $2,150,000 after acquiring an additional 842 shares during the last quarter. Founders Capital Management LLC boosted its stake in Regeneron Pharmaceuticals by 7.0% during the 2nd quarter. Founders Capital Management LLC now owns 8,274 shares of the biopharmaceutical company's stock valued at $4,344,000 after acquiring an additional 538 shares during the last quarter. PGGM Investments boosted its stake in Regeneron Pharmaceuticals by 159.7% during the 2nd quarter. PGGM Investments now owns 84,397 shares of the biopharmaceutical company's stock valued at $44,308,000 after acquiring an additional 51,900 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Regeneron Pharmaceuticals by 3.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,629 shares of the biopharmaceutical company's stock valued at $16,255,000 after acquiring an additional 955 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.